Use of somastatin analogues in the treatment of patients with acromegaly: options for the drug Somatuline® Autogel® use
- Authors: Pronin VS1, Poteshkin Y.E1, Pronin V1, Poteshkin Y1
-
Affiliations:
- Issue: No 3 (2010)
- Pages: 64-67
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278242
- ID: 278242
Cite item
Full Text
Abstract
We consider the modern potentials for use of selective somatostatin analogs in the treatment of acromegaly. The comparative data for the analogues widely used in clinical practice (preparations of octreotide and lanreotide) are presented. The results of clinical studies aimed to evaluation of effectiveness of selective analogue of somatostatin with prolonged action - Somatuline®Autogel® - in acromegaly are considered. Mechanisms of antisecretory and antiproliferative effects of the drug and the optimal scheme of its use are discussed.
References
- Abrams P, Alexopoulou O, Abs R, et al. Optimalisation and cost management of lanreotide-autogel therapy in acromegaly. Eur J Endocr 2007;157:571-77.
- Barrie R, Woltering EA, Hajarizadeh H, et al. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. Journal of Surgical Research 1993,55:446-450.
- Bevan JS, Newell-Price J, Wass JAH, et al Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective. Clinical Endocrinology 2008;68:343-49.
- Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60,90 or 120 mg every 28 days. Clin Endocrinology 2005;63:514-19.
- Casarini AP, Jallad RS, Pinto EM, et al. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 2009;12(4):297-303.
- Colao A, Auriemma RS, Rebora A, et al Significant tumour shrinkage after 12 months of Lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinology 2009;71:237-45.
- Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumour shrinkage. J Clin Endocrnol Metab 2006,64:342-351.
- Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87(8):3013-8.
- Lombardi G, Minuto F, Tamburrano G, et al Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 2009;32:297-303.
- Mercado M, Borges F, Bouterfa H, et al. A Prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinology 2007;66:859-68.
- Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinology 2007;63:514-19.
- Toledano Y, Rot L, Greenman Y, et al. Efficacy of long-term lanreotide treatment in patients with acromegaly. Pituitary 2009;12(4):285-93.
Supplementary files
